Mirova Trims Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Mirova reduced its stake in Boston Scientific Corporation by 11.0% during the first quarter, now holding 22,330 shares worth approximately $2.25 million.
• Insider trading activity included Director Edward J. Ludwig selling 4,000 shares and CEO Michael F. Mahoney selling 164,443 shares, indicating notable declines in their respective holdings.
• Boston Scientific's latest quarterly earnings surpassed expectations, reporting $0.75 earnings per share and $5.06 billion in revenue, marking a 22.8% increase year-over-year.

Mirova lowered its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,330 shares of the medical equipment provider's stock after selling 2,772 shares during the period. Mirova's holdings in Boston Scientific were worth $2,253,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Colonial Trust Co SC raised its position in Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the period. Investment Management Corp VA ADV purchased a new stake in Boston Scientific in the 4th quarter worth about $25,000. Sunbeam Capital Management LLC purchased a new stake in Boston Scientific in the 4th quarter worth about $26,000. Y.D. More Investments Ltd purchased a new stake in Boston Scientific in the 1st quarter worth about $27,000. Finally, Ameriflex Group Inc. purchased a new stake in Boston Scientific in the 4th quarter valued at about $31,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

NYSE:BSX traded down $0.34 during mid-day trading on Friday, reaching $105.42. 1,435,244 shares of the stock were exchanged, compared to its average volume of 7,467,302. The company has a 50 day simple moving average of $104.45 and a 200-day simple moving average of $102.17. The stock has a market capitalization of $156.20 billion, a P/E ratio of 62.76, a P/E/G ratio of 2.55 and a beta of 0.66. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1 year low of $79.53 and a 1 year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the company's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,347,824.96. This represents a 24.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BSX shares. Barclays boosted their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Robert W. Baird raised their price objective on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Citigroup reissued a "buy" rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Finally, UBS Group increased their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.